India, Nov. 11 -- Harvard Bioscience, Inc. (HBIO), on Tuesday reported third-quarter 2026 financial results, with revenue increasing 8% year over year to $22.2 million.
The company reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%, while updating its adjusted EBITDA outlook.
Company Profile
Harvard Bioscience is a global developer, manufacturer and marketer of specialized products used in life science research. Its portfolio includes Cellular & Molecular Technology (CMT) products and New Product Innovation (NPI) platforms.
Q3 2026 Financial Highlights
For the quarter ended September 30, 2026, revenue increased to $22.2 million from $20.6 million in the prior-year quarter. The latest quarter included an unfavorable forei...